FL-EIGHT-SLEEP
Eight Sleep , the world's first sleep fitness company, today announced that the Mercedes-AMG Petronas Formula 1 Team has named the company as Official Team Supplier in a joint effort to support the team’s preparations for an expansive 2022 Formula 1 schedule. The Mercedes-AMG Petronas team including drivers, Lewis Hamilton, George Russell, as well as Team Principal, Toto Wolff, will have access to Eight Sleep’s suite of products to optimize their sleep and ensure peak performance this and next season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220318005290/en/
The Mercedes-AMG Petronas F1 Team rigorously looks for ways to improve the performance of the car and the team. Eight Sleep’s next-generation sleep technology is engineered to support the technical and human demands of the intense 2022 F1 schedule, enabling the 8x Champions to maintain their long term success. The Mercedes-AMG Petronas F1 Team joins Eight Sleep along with more than 200 professional athletes who rely on Eight Sleep to power their recovery through the Pod Pro’s advanced thermoregulation and sleep technology.
In addition to Eight Sleep’s branding being featured on the team’s car for the inaugural Miami Grand Prix, the Eight Sleep logo will be featured on all the car covers for the duration of the season. Eight Sleep will support Mercedes-AMG Petronas F1 team members to power their performance through their innovative sleep technology Data has shown that Eight Sleep products help 49% of Eight Sleep members see an increase in their HRV of at least 10% one week after sleeping on the Pod.
With grueling schedules that consist of training, racing, and traveling, it’s critical that team members properly refuel and recover in order to perform their best. When they are pushing their bodies to their limits, in between the training, racing and hectic traveling schedules, the team needs to properly recover and refuel. Eight Sleep’s thermoregulation is designed to recharge the team to peak energy levels, which will be critical for the Mercedes-AMG Petronas Formula One Team in 2022. Additionally, the Eight Sleep App leverages the product’s sensor technology to provide daily reports on key health metrics, such as heart rate, HRV, sleeping stages, and more, giving the team the ability to build better health regimes and optimize their sleep.
“Our team is made up of over 2,000 people across Brackley and Brixworth, all of whom perform at their peak every day in a sport where every single detail matters. To achieve the level of sustained performance that is required to compete in Formula 1, we are relentless in exploring all possible optimizations, including sleep. By partnering with Eight Sleep we are looking to utilize their technology during the upcoming season while also spreading a key message about the importance of recovery when you aim for peak performance,” said Toto Wolff, Team Principal and CEO of the Mercedes-AMG Petronas F1 Team.
“Eight Sleep, and myself personally, are thrilled to partner with Mercedes-AMG Petronas Formula One and power their team’s sleep so they can continue to perform at the highest level,” said Matteo Franceschetti, Co-Founder and CEO of Eight Sleep. “Growing up in Italy, Formula One was a huge part of my life – from racing cars with my father to starting my first business taking pictures of racing cars at local tracks. Mercedes-AMG Petronas F1’s commitment to constant innovation and improvement is what we strive for at Eight Sleep. We will work together to improve the team’s sleep and recovery for a successful win at this year’s Grand Prix races.”
“We’re delighted to welcome Eight Sleep to the team and to start working with them to develop and innovate around our sleep and recovery programmes,” said Richard Sanders, Commercial Director of the Mercedes-AMG Petronas F1 Team. “Eight Sleep’s approach to reimagining sleep is very similar to how we operate. They’re obsessed with performance, the fine details and ensuring our team gets the rest they need to perform at their very best.”
The Pod Pro by Eight Sleep
The Pod Pro by Eight Sleep is the most advanced solution on the market for thermoregulation. The Pod Pro retains vital features of the original and award-winning Pod, introducing new Room Climate and Weather Response, a Comfort Blend™ Integrated Topper, GentleRise™ Wake Up Technology, and double the amount of sensors enabling new Heart Rate Variability monitoring and a Daily Health Check report. The advancements in the Pod Pro help everyone with their rest and recovery – from elite athletes to everyday consumers. The product transforms any ordinary bed into an advanced health platform that fuels both performance and longevity.
Current and former Eight Sleep athletes include Red Gerard (2018 Gold Medalist, Snowboarding), Brooke Wells (Two-time individual CrossFit Gamesathlete), Apolo Ohno (Two-Time Gold Medalist, Speed Skating), Justin Medeiros (CrossFit Champion 2021), Daniel Sturridge (English Soccer Player), Daryl Homer (2020, and 2016 Silver Medalist, Fencing), and Jane Campbell (2020 Bronze Medalist, Soccer). Eight Sleep’s athlete-investors include Alex Rodriguez (retired MLB athlete and entrepreneur), Matthew Dellavedova (2020 Bronze Medalist, Basketball), Kris Bryant (San Francisco Giants outfielder), and J.D. Martinez (Boston Red Sox outfielder).
About Eight Sleep
Eight Sleep is the world's first sleep fitness company with a mission to fuel human potential through optimal sleep. Eight Sleep leverages thermoregulation, data, and technology to restore individuals to their peak energy levels every morning. Eight Sleep was named one of Fast Company's “Most Innovative Companies of 2022” and “Most Innovative Companies of 2018,” and recognized two years in a row by TIME's “Best Inventions of the Year.” To learn more, visit eightsleep.com .
About Mercedes-AMG Petronas Formula One
Mercedes-AMG Petronas Formula One Team is the works team of Mercedes-Benz, competing at the pinnacle of motorsport – the FIA Formula One™ World Championship.
Formula One is like nothing else in the sporting sphere. It’s a demanding technical and human challenge, combining cutting-edge technologies and innovation, high-performance management and elite teamwork.
At Mercedes-AMG Petronas Formula One Team, a group of passionate and determined people work to design, develop, manufacture and race the cars driven by seven-time World Champion Lewis Hamilton and young star George Russell.
The team has set a new benchmark for F1 success during the sport’s current Hybrid era, winning consecutive Drivers’ and Constructors’ World Championships in 2014, 2015, 2016, 2017, 2018, 2019 and 2020, and the Constructors’ Championship in 2021. During those title-winning seasons, the team has scored 111 wins, 232 podium finishes, 118 pole positions, 81 fastest laps and 53 one-two finishes from 160 race starts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220318005290/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
